# Physical activity and competitive sport safety for children affected by inherited cardiac conditions and selected acquired cardiomyopathies: emerging evidence and areas for further inquiry

**Authors:** Scott Kendall, Andrea Greco, Nicoletta Cantarutti, Andreia Constante, Daniel Diaz-Gil, Simon D’hulst, Roger Esmel-Vilomara, José Luis López-Guillén, Katarzyna Luczak-Wozniak, Gian L. Ragazzoni, Wannes Renders, Iulia Rodoman, Christophe Vô, Sara Moscatelli, Terrence Prendiville, Pascal McKeown, Georgia Sarquella-Brugada, Frank Casey

PMC · DOI: 10.1007/s00431-026-06768-y · European Journal of Pediatrics · 2026-03-04

## TL;DR

This review discusses how children with inherited heart conditions can safely participate in sports through personalized risk assessments and shared decision-making.

## Contribution

New evidence shows that guided sports participation is safe for children with heart conditions and can improve heart function in cancer survivors.

## Key findings

- Observational studies show sports participation is safe with proper risk assessment.
- Cardiac rehab improves heart function in young cancer survivors.

## Abstract

Physicians tasked with caring for children with inherited cardiac conditions (ICCs) face complex decisions regarding safe participation in physical activity and competitive sport. Historically, concerns over sudden cardiac death (SCD) and disease progression led to widespread exercise restrictions. However, emerging evidence and evolving guidelines now support a more nuanced, risk-based approach. This narrative review explores current recommendations for exercise in children with major ICCs—including channelopathies, cardiomyopathies, and aortopathies. It highlights advances in risk stratification, the use of exercise testing, cardiac imaging, and genetic information to guide individualised recommendations. Shared decision-making (SDM) is emphasised as central to balancing arrhythmic and disease progression risk with the substantial physical, psychological, and social benefits of exercise. The review also discusses non-inherited conditions like anthracycline-induced cardiomyopathy and myocarditis. Despite progress, substantial variation exists in international guidelines, and there remains a paucity of paediatric-specific data. This poses a significant challenge and often necessitates utilising adult data when making decisions for children.

Conclusion: Further research, including registries and multi-centre studies, is essential to improve evidence-based recommendations and empower clinicians, patients, and families in decision-making. A personalised approach—grounded in expertise, communication, and longitudinal follow-up—is critical to safely supporting children with ICCs in leading active, fulfilling lives.

What is Known:

• Inherited cardiac conditions (ICCs) are associated with ventricular arrhythmia, heart failure, and sudden cardiac death (SCD) prompting caution around sports and physical activity.

• Myocarditis and anthracycline-induced cardiomyopathy are common aetiologies of cardiac dysfunction.

What is New:

• Observational studies in paediatric cohorts are reassuring for continued participation in sports following guideline-directed shared decision-making.

• Cardiac rehabilitation improves left ventricular function in paediatric cancer survivors.

The online version contains supplementary material available at 10.1007/s00431-026-06768-y.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252), sudden cardiac death (MONDO:0007264), myocarditis (MONDO:0004496)

## Full-text entities

- **Genes:** KCNQ1 (potassium voltage-gated channel subfamily Q member 1) [NCBI Gene 3784] {aka ATFB1, ATFB3, JLNS1, KCNA8, KCNA9, KVLQT1}, KCNH2 (potassium voltage-gated channel subfamily H member 2) [NCBI Gene 3757] {aka ERG-1, ERG1, H-ERG, HERG, HERG1, Kv11.1}, TMEM43 (transmembrane protein 43) [NCBI Gene 79188] {aka ARVC5, ARVD5, AUNA3, EDMD7, EDMD7; AUNA2, LUMA}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, FLNC (filamin C) [NCBI Gene 2318] {aka ABP-280, ABP280A, ABPA, ABPL, ARVC15, CMD1PP}, PLN (phospholamban) [NCBI Gene 5350] {aka CMD1P, CMH18, PLB}, PKP2 (plakophilin 2) [NCBI Gene 5318] {aka ARVD9}, RBM20 (RNA binding motif protein 20) [NCBI Gene 282996], DSP (desmoplakin) [NCBI Gene 1832] {aka DCWHKTA, DP}, SCN5A (sodium voltage-gated channel alpha subunit 5) [NCBI Gene 6331] {aka CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD}
- **Diseases:** inflammation (MESH:D007249), NDLVC (MESH:C565277), conditions (MESH:D020763), aortic disease (MESH:D001018), fibrosis (MESH:D005355), syncope (MESH:D013575), VA (MESH:C563443), RTP (MESH:D012587), abnormal blood pressure response (MESH:D006973), hypertrophy of the left ventricle (MESH:D017379), LQT3 (MESH:C537034), BrS (MESH:D053840), LVOT obstruction (MESH:D000092242), deaths (MESH:D003643), connective tissue disorders (MESH:D003240), cardiac events (MESH:D002318), CPVT (MESH:C536334), DCM (MESH:D002311), aneurysm (MESH:D000783), AoD (MESH:D000784), Cancer (MESH:D009369), aortic involvement (MESH:C564676), cardiac arrest (MESH:D006323), HTAD (MESH:D065627), Channelopathies (MESH:D053447), ventricular dysfunction (MESH:D018754), chest (MESH:D013898), ICD (MESH:D057873), ventricular dilatation (MESH:C566255), left ventricular dysfunction (MESH:D018487), congestive heart failure (MESH:D006333), VAs (MESH:D001145), LQT2 (MESH:C563614), ACM (MESH:D019571), obesity (MESH:D009765), CM (MESH:D009202), leukaemia (MESH:D015458), HCM (MESH:D002312), chronotropic incompetence (MESH:D001022), Myocarditis (MESH:D009205), MFS (MESH:D008382), SCD (MESH:D016757), LCSD (MESH:D006331), LDS (MESH:D055947), cardiotoxic (MESH:D066126), ischaemia (MESH:D007511), blunt trauma to (MESH:D014949), ventricular couplets (MESH:D014693), PVCs (MESH:D018879), genetic disorders (MESH:D030342), RCM (MESH:D002313), arrhythmic (OMIM:212500), non-sustained ventricular tachycardia (MESH:D017180), Congenital long QT syndrome (MESH:D008133), EAPC (MESH:D004675), systolic and diastolic dysfunction (MESH:D054144), LQT1 (MESH:D029597)
- **Chemicals:** Catecholaminergic (-), flecainide (MESH:D005424), nadolol (MESH:D009248), Mavacamten (MESH:C000605992), Anthracycline (MESH:D018943), catecholamine (MESH:D002395)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.Arg14del

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957645/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957645/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957645/full.md

---
Source: https://tomesphere.com/paper/PMC12957645